ATE232536T1 - N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4- - Google Patents

N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-

Info

Publication number
ATE232536T1
ATE232536T1 AT98958672T AT98958672T ATE232536T1 AT E232536 T1 ATE232536 T1 AT E232536T1 AT 98958672 T AT98958672 T AT 98958672T AT 98958672 T AT98958672 T AT 98958672T AT E232536 T1 ATE232536 T1 AT E232536T1
Authority
AT
Austria
Prior art keywords
compound
benzyloxycarbonyl
oxo
amino
disease
Prior art date
Application number
AT98958672T
Other languages
English (en)
Inventor
Gerald Paul Schielke
Aurash Shahripour
Original Assignee
Warner Lambert Co
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Abbott Gmbh & Co Kg filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE232536T1 publication Critical patent/ATE232536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98958672T 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4- ATE232536T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20
PCT/US1998/024848 WO1999036426A1 (en) 1998-01-20 1998-11-20 N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE)

Publications (1)

Publication Number Publication Date
ATE232536T1 true ATE232536T1 (de) 2003-02-15

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98958672T ATE232536T1 (de) 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-

Country Status (11)

Country Link
EP (1) EP1049703B1 (de)
JP (1) JP2002509153A (de)
AT (1) ATE232536T1 (de)
AU (1) AU1466399A (de)
CA (1) CA2309546A1 (de)
DE (1) DE69811404T2 (de)
DK (1) DK1049703T3 (de)
ES (1) ES2193589T3 (de)
PT (1) PT1049703E (de)
WO (1) WO1999036426A1 (de)
ZA (1) ZA99369B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
WO2001077079A2 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
CA2405561A1 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
AU2001222501A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
EP1301490A2 (de) * 2000-07-18 2003-04-16 Neurogen Corporation 5-substituierte 2-aryl-4-pyrimidinone
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
JP2004517074A (ja) 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
CA2462645A1 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
KR101135765B1 (ko) 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
EP1910379B1 (de) 2005-07-28 2011-10-19 Vertex Pharmaceuticals Incorporated Caspase-hemmer-propharmaka
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4526469A1 (de) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Verfahren zur beurteilung der erschöpfung von hämatopoetischen stammzellen durch chronische entzündung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
CA2186511C (en) * 1994-03-31 2009-02-10 Roland E. Dolle Pyrimidinyl derivatives as interleukin inhibitors

Also Published As

Publication number Publication date
PT1049703E (pt) 2003-06-30
ES2193589T3 (es) 2003-11-01
AU1466399A (en) 1999-08-02
DE69811404T2 (de) 2003-12-04
JP2002509153A (ja) 2002-03-26
DK1049703T3 (da) 2003-06-02
EP1049703B1 (de) 2003-02-12
EP1049703A1 (de) 2000-11-08
CA2309546A1 (en) 1999-07-22
WO1999036426A1 (en) 1999-07-22
ZA99369B (en) 1999-07-20
DE69811404D1 (de) 2003-03-20

Similar Documents

Publication Publication Date Title
DK1049703T3 (da) N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym
NO991674D0 (no) Interleukin-1<Beta>omdannelsesenzym-inhibitor-sulfonamider
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
EP1034164A4 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
EA199800923A1 (ru) Новые 2,3-двузамещенные 4(3н)-хиназолины
ATE206409T1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h- benzo(b)(1,5)-diazepin-3-yl)-acetamide
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
DE69811360D1 (de) Diazepinoindolone als phophodiesterase 4 inhibitoren
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
IL129124A0 (en) Sulfonamide substituted aspartic acid interleukin -1beta converting enzyme inhibitors
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
EP0637961A4 (de) Verfahren zur behandlung von entzündlichen darmerkrankungen mit leukotriensynthese inhibitoren.
ATE294780T1 (de) Arylpiperidin- und aryl-1,2,5,6- tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
EP0785989A4 (de) Mikrobielle synthese von hemmstoffen der hiv-protease
TNSN99051A1 (fr) Halogenures de phenoxyphenylsulfonyle et procede pour leur preparation
EP1305008A4 (de) Verbesserte formen von pharmazeutischen wirkstoffen und verfahren zu deren herstellung
EA200001105A1 (ru) 10-камфорсульфонат пароксетина для лечения нарушений цнс
FR2743811B1 (fr) Procede de fabrication d'alkenyl succinimides ou de polyalkenyl succinimides
FR2772753B1 (fr) Procede de synthese d'acetals
FR2800391B1 (fr) Procede de renovation d'etuves
ITRM940468A0 (it) "impiego di esteruretani per ls riconcia".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1049703

Country of ref document: EP

REN Ceased due to non-payment of the annual fee